- New Product Sales Up 32%, International Strategy Upgraded -Shanghai, August 28, 2025 -- Luye Pharma Group (2186.HK) today announced its 2025 half-year results and latest developments. During the rep...
Boan Biotech (6955.HK) today announced its 2025 half-year results and latest developments.During the reporting period, the company's total revenue was RMB 393 million, up 8% YoY, and the contribut...
Yantai, August 8, 2025 –- Boan Biotech announced that China’s National Medical Products Administration (NMPA) has granted marketing approval to its Boyouping®(Dulaglutide Injection), indic...
Shanghai, April 10, 2025 – Luye Pharma Group announced the recent launch of its rotigotine transdermal patch, Rotigotine Luye, in the UK. This product is indicated for the treatment of the signs...
Tokyo, March 31, 2025 – Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Mini...
* Strong growth of RMB 190 million in net profit* Time to reap the benefits of R&DBoan Biotech (6955.HK) today announced its annual results for fiscal year 2024 and latest developments.In the repo...
On March 24, 2025, Luye Diagnostics announced that "You Shu Xin", a Helicobacter pylori nucleic acid test kit independently developed by its subsidiary Cellrun (Shanghai) Medical Technology ...
Shanghai, January 15, 2025 - Luye Pharma Group today announced the enrollment of the first patient in China for a Phase Ⅱ clinical trial of LY03015, a VMAT2 (vesicular monoamine transporter 2) inhibi...
Boan Biotech announced that it has signed a licensing agreement for commercializing its self-developed Denosumab Injection (BA6101 and BA1102) in the Brazilian market with a strategic partner.Under th...
Boan Biotech announced that the first patient has been dosed in the Phase 1 clinical trial of BA1302, a novel CD228-directed antibody drug conjugate (ADC),which is the only CD228 ADC undergoing clinic...
TOP